Protein-protein interactions in neurodegenerative diseases
AssigneeMyriad Genetics, Inc.
InventorsJean-Marc Roch, Paul L. Bartel, Karen Heichman
Life of this patent
Estimating the term…
Abstract
The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.
Claims79
A method for modulating, in a cell, a protein complex having a first protein which is CIB interacting with a second protein which is MLK2, said method comprising:
- administering to said cell a compound capable of modulating said protein complex.
A method for modulating, in a cell, a protein complex having a first protein which is CIB interacting with a second protein which is MLK2, said method comprising:
- administering to said cell a peptide capable of interfering with the interaction between said first protein and said second protein, wherein said peptide is associated with a transporter capable of increasing cellular uptake of said peptide.
A method for modulating, in a cell, the interaction of MLK2 with a ligand, said method comprising:
- administering to said cell a compound capable of modulating said interaction.
A method for modulating neuronal death in a patient having a neurodegenerative disorder comprising:
- modulating a protein complex having a first protein which is CIB interacting with a second protein which is MLK2.
A method for modulating neuronal death in a patient having neurodegenerative disorder comprising:
- administering to the patient a compound capable of modulating a protein complex having a first protein which is CIB interacting with a second protein which is MLK2.
A method for modulating neuronal death in a patient having neurodegenerative disorder comprising:
- administering to said cell a peptide capable of interfering with the interaction between a first protein being CIB and a second protein being MLK2, wherein said peptide is associated with a transporter capable of increasing cellular uptake of said peptide.
A method for treating a neurodegenerative disorder comprising:
- administering to a patient in need of treatment a compound capable of modulating a protein complex having a first protein which is CIB interacting with a second protein which is MLK2.
A method for treating a neurodegenerative disorder comprising:
- administering to said cell a peptide capable of interfering with the interaction between said first protein being CIB and said second protein being MLK2, wherein said peptide is associated with a transporter capable of increasing cellular uptake of said peptide.
A method for treating a neurodegenerative disorder comprising:
- administering to a patient in need of treatment a compound capable of modulating the activity of MLK2.
A method of modulating MLK2 activity in a cell comprising:
- administering to said cell a compound capable of modulating said MLK2.
A method for modulating MLK2 activities in a cell comprising:
- administering to said cell a peptide having a contiguous span of at least 4 amino acids of CIB and capable of binding MLK2, wherein said peptide is associated with a transporter capable of increasing cellular uptake of said peptide.
Dependencies are inferred from the claim text.